Menu
Menu
Torrent Pharmaceuticals has been issued a USFDA Form 483 with five observations following an inspection of their Gujarat manufacturing facility, highlighting critical compliance areas that need immediate attention. After a thorough inspection, the USFDA issued a Form 483 to Torrent Pharmaceuticals with five key observations, emphasizing the need for stringent quality control and documentation practices at their Gujarat plant. The USFDA's recent inspection of Torrent Pharmaceuticals' Gujarat unit resulted in a Form 483 with five observations, shedding light on compliance issues that could impact future product approvals. Torrent Pharmaceuticals faces a significant regulatory challenge as the USFDA issues a Form 483 with five observations after inspecting their Gujarat facility, focusing on critical areas of improvement. The USFDA's Form 483 issued to Torrent Pharmaceuticals' Gujarat plant includes five critical observations, raising concerns about compliance and the potential effects on the company's product approvals.